Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
646.180
Open
639.500
VWAP
638.63
Vol
6.93M
Mkt Cap
605.19B
Low
629.398
Amount
4.42B
EV/EBITDA(TTM)
26.21
Total Shares
950.41M
EV
637.64B
EV/OCF(TTM)
58.29
P/S(TTM)
10.76
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD).
Show More
Get winning stock picks in minutes
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
15.81B
+24.18%
6.544
+95.93%
17.27B
+27.58%
6.890
+29.51%
15.96B
+39.55%
6.282
+432.41%
Estimates Revision
The market is revising Upward the revenue expectations for Eli Lilly and Company (LLY) for FY2025, with the revenue forecasts being adjusted by 2.83% over the past three months. During the same period, the stock price has changed by -14.29%.
Revenue Estimates for FY2025
Revise Upward
+2.83%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+3.5%
In Past 3 Month
Stock Price
Go Down
-14.29%
In Past 3 Month
20 Analyst Rating
59.05% Upside
Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1017 USD with a low forecast of 835.00 USD and a high forecast of 1190 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
3 Hold
0 Sell
Strong Buy
59.05% Upside
Current: 639.430
Low
835.00
Averages
1017
High
1190
59.05% Upside
Current: 639.430
Low
835.00
Averages
1017
High
1190
Deutsche Bank
Buy
downgrade
$900
2025-08-11
New
Reason
Deutsche Bank
Price Target
$900
2025-08-11
New
downgrade
Buy
Reason
Deutsche Bank lowered the firm's price target on Eli Lilly to $900 from $1,010 and keeps a Buy rating on the shares.
Morgan Stanley
Overweight
downgrade
2025-08-08
New
Reason
Morgan Stanley
Price Target
2025-08-08
New
downgrade
Overweight
Reason
Morgan Stanley lowered the firm's price target on Eli Lilly to $1,028 from $1,135 and keeps an Overweight rating on the shares. Debates on the competitive profile of oral orforglipron in obesity drove the weakness in shares yesterday, notes the analyst, who says these concerns overshadowed a "solid" Q2 EPS report. While the firm notes that it lowered estimates for its oral weight loss pill bull case, its base case estimates for the drug are unchanged and it views the selloff as "overdone."
JPMorgan
Overweight
maintain
$1,100
2025-08-08
New
Reason
JPMorgan
Price Target
$1,100
2025-08-08
New
maintain
Overweight
Reason
JPMorgan views the post-earnings selloff in shares of Eli Lilly as providing a "compelling" entry point. The Q2 report came in well ahead of consensus estimated and Lilly is raised guidance, which should dispel some weight loss market concerns, the analyst tells investors in a research note. However, the firm says the bigger focus was on orforglipron's Phase 3 obesity data where weight loss came in slightly below expectations. JPMorgan does not see 1-2 percentage points lower weight loss as meaningfully changing the use case for orforglipron. It keeps an Overweight rating on Lilly shares with a $1,100 price target.
UBS
Buy
downgrade
$895
2025-08-08
New
Reason
UBS
Price Target
$895
2025-08-08
New
downgrade
Buy
Reason
UBS lowered the firm's price target on Eli Lilly to $895 from $1,050 and keeps a Buy rating on the shares. The beat and raise quarter was overshadowed by the weaker than expected ATTAIN-1 topline, the analyst tells investors in a research note.
Leerink
Outperform -> Market Perform
downgrade
$715
2025-08-07
Reason
Leerink
Price Target
$715
2025-08-07
downgrade
Outperform -> Market Perform
Reason
Leerink downgraded Eli Lilly to Market Perform from Outperform with a $715 price target.
Leerink
Leerink
Outperform -> Market Perform
downgrade
$944 -> $715
2025-08-07
Reason
Leerink
Leerink
Price Target
$944 -> $715
2025-08-07
downgrade
Outperform -> Market Perform
Reason
As previously reported, Leerink downgraded Eli Lilly (LLY) to Market Perform from Outperform with a price target of $715, down from $944. Following "disappointing" initial results for orforglipron, the company's oral GLP-1, the firm is lowering its long-term projections and notes that its "investment thesis has changed" as it no longer expects upward pressure on long-term consensus expectations. The firm also notes that Lilly's major competitor Novo Nordisk (NVO) is struggling and may need to continue to use price to compete in its duopoly while the firm expects growing competition from various competitors starting late decade.
See All Ratings
Get winning stock picks in minutes
Valuation Metrics
The current forward P/E ratio for Eli Lilly and Co (LLY.N) is 23.42, compared to its 5-year average forward P/E of 39.57. For a more detailed relative valuation and DCF analysis to assess Eli Lilly and Co 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Undervalued
5Y Average PE
39.57
Current PE
23.42
Overvalued PE
52.20
Undervalued PE
26.94
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Undervalued
5Y Average EV/EBITDA
29.59
Current EV/EBITDA
19.48
Overvalued EV/EBITDA
37.90
Undervalued EV/EBITDA
21.29
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
10.63
Current PS
8.59
Overvalued PS
13.86
Undervalued PS
7.41
Financials
Annual
Quarterly
FY2025Q2
YoY :
+37.64%
15.56B
Total Revenue
FY2025Q2
YoY :
+63.12%
7.02B
Operating Profit
FY2025Q2
YoY :
+90.78%
5.66B
Net Income after Tax
FY2025Q2
YoY :
+91.77%
6.29
EPS - Diluted
FY2025Q2
YoY :
+1923.66%
1.28B
Free Cash Flow
FY2025Q2
YoY :
+4.29%
84.27
Gross Profit Margin - %
FY2025Q2
YoY :
-99.03%
-0.09
FCF Margin - %
FY2025Q2
YoY :
+38.59%
36.38
Net Margin - %
FY2025Q2
YoY :
+33.24%
28.86
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
226.2M
USD
2
3-6
Months
205.9M
USD
3
6-9
Months
2.2B
USD
8
0-12
Months
23.3M
USD
1
Bought
0-3
5
2.9M
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
9.3K
Volume
2
3-6
Months
922.2K
Volume
23
6-9
Months
182.5K
Volume
26
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
20
1.2M
Volume
Months
6-9
41
2.4M
Volume
Months
0-12
1
1.5K
Volume
Months
Congress Trading
Congress areBuying! The buying amount has increased100%over the last month.
Sold
0-3
Months
32.5K
USD
1
3-6
Months
336.0K
USD
15
6-9
Months
163.0K
USD
12
0-12
Months
121.5K
USD
6
Bought
0-3
3
24.0K
USD
Months
3-6
9
288.0K
USD
Months
6-9
4
166.0K
USD
Months
0-12
1
32.5K
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
226.2M
USD
2
3-6
Months
205.9M
USD
3
6-9
Months
2.2B
USD
8
0-12
Months
23.3M
USD
1
Bought
0-3
5
2.9M
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
LLY News & Events
Events Timeline
2025-08-12 (ET)
2025-08-12
13:11:09
Eli Lilly sued by Texas AG, company accused of 'bribing providers'
2025-08-08 (ET)
2025-08-08
09:29:30
Trump, pharma industry discuss increasing medicine spending abroad, Reuters says
2025-08-07 (ET)
2025-08-07
13:09:37
Video: Why Eli Lilly Is Underperforming Today
Sign Up For More Events
Sign Up For More Events
News
9.5
08-11TipRanksPinnedWhy Eli Lilly’s (LLY) Tasty Q2 Earnings Left a Bitter Aftertaste
5.0
08-12MarketWatchThese Eli Lilly executives have been scooping up stock after its big drop
5.0
08-12Barron'sEli Lilly CEO Buys $1M of Stock After Share-Price Drop on Obesity Drug Data
Sign Up For More News
People Also Watch
BRK.B
Berkshire Hathaway Inc
470.390
USD
+1.22%
HD
Home Depot Inc
396.000
USD
+2.19%
COST
Costco Wholesale Corp
991.250
USD
+0.25%
CRM
Salesforce Inc
231.660
USD
-0.44%
MRK
Merck & Co Inc
80.300
USD
+0.34%
CVX
Chevron Corp
154.440
USD
+0.65%
PG
Procter & Gamble Co
155.090
USD
+0.07%
JNJ
Johnson & Johnson
172.780
USD
-0.60%
PFE
Pfizer Inc
24.650
USD
+0.28%
UNH
UnitedHealth Group Inc
261.570
USD
+3.65%
FAQ
What is Eli Lilly and Co (LLY) stock price today?
The current price of LLY is 639.43 USD — it has increased 0.66 % in the last trading day.
What is Eli Lilly and Co (LLY)'s business?
What is the price predicton of LLY Stock?
What is Eli Lilly and Co (LLY)'s revenue for the last quarter?
What is Eli Lilly and Co (LLY)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Eli Lilly and Co (LLY)'s fundamentals?
How many employees does Eli Lilly and Co (LLY). have?